Meeting Overview - The 31st temporary meeting of the 8th Supervisory Board of Meinian Health Industry Holdings Co., Ltd. was held on July 11, 2025, via electronic means, with all three supervisors present [1][2]. Proposal for Asset Acquisition - The company plans to acquire equity stakes in 11 companies, including Hengyang Meinian Health Examination Center Co., Ltd., and minority stakes in 5 subsidiaries, including Zhengzhou Meijian Health Management Co., Ltd., through a share issuance [1][2][3]. Approval of Proposals - The Supervisory Board approved the proposal regarding the company's compliance with conditions for issuing shares to purchase assets, with a unanimous vote of 3 in favor [2][3]. - The proposal for the share issuance to purchase assets and related transactions was also approved, with a unanimous vote of 3 in favor [2][3]. Transaction Details - The transaction involves 37 counterparties, including individuals and companies, with specific equity stakes and transaction prices outlined for each [3][4]. - The transaction prices for key stakes include: - 84% of Hengyang Meinian for 33.6 million yuan - 81% of Ningde Meinian for 30.78 million yuan - 75% of Yantai Meinian for 35.8125 million yuan - 49% of Yantai Meinian Fudian for 12.25 million yuan - 90% of Feicheng Meinian for 22.5 million yuan [3][4]. Share Issuance Pricing - The share issuance price is set at 4.74 yuan per share, which is not less than 80% of the average trading price over the previous 120 trading days [5][6]. - The issuance price may be adjusted based on market conditions during the period from the pricing base date to the issuance date [6][7]. Lock-up Period and Profit Distribution - A lock-up period of 36 months is established for shares acquired by the counterparty, with conditions for extension based on stock performance [9][10]. - The profits generated during the transition period will belong to the company, while losses will be compensated by the counterparties based on their ownership percentages [10][11]. Compliance and Regulatory Approvals - The proposals will be submitted to the shareholders' meeting for approval, requiring a two-thirds majority of the voting rights present [2][11]. - The company has confirmed compliance with relevant laws and regulations regarding the asset acquisition and share issuance [12][13]. Future Shareholder Returns - The company has developed a three-year shareholder return plan for 2025-2027 to enhance shareholder value and ensure reasonable returns [26].

Core Viewpoint - The company plans to acquire significant stakes in multiple health management subsidiaries through a share issuance, which is expected to enhance its asset scale and profitability without diluting immediate returns per share [1][3]. Group 1: Transaction Details - The company intends to purchase 84% of Hengyang Meinian Health Checkup Center, 81% of Ningde Meinian Health Management, and several other stakes in various health management companies, totaling multiple acquisitions [1]. - The transaction is structured to ensure that the company's earnings per share (EPS) will not be diluted post-transaction, with projected increases in net profit attributable to the parent company [2][3]. Group 2: Measures to Mitigate Dilution Risks - The company plans to accelerate the integration of the acquired companies to enhance profitability and operational efficiency [3]. - A commitment to improve corporate governance and operational efficiency has been established, ensuring a robust management structure and clear responsibilities among various governance bodies [4]. - The company will refine its profit distribution policy to ensure fair returns to all shareholders while maintaining sustainable growth [6]. Group 3: Commitments from Stakeholders - The actual controller and senior management have issued commitments to uphold measures that protect immediate returns, ensuring no undue interference in company operations [6]. - Specific commitments include linking compensation plans to the execution of measures aimed at mitigating dilution of immediate returns [6].

Core Points - The company intends to acquire significant equity stakes in multiple health management and inspection centers through a share issuance [1][2] - The board believes that the company does not fall under any prohibitive conditions outlined in the newly implemented "Regulations on the Registration Management of Securities Issuance by Listed Companies" [2] Group 1 - The company plans to purchase 84% of Hunan Meinian Health Examination Center, 81% of Ningde Meinian Health Management, 75% of Yantai Meinian Health Management, and several other stakes in various health management companies [1] - The board has conducted a thorough analysis and concluded that there are no disqualifying conditions for the share issuance, such as negative audit opinions or administrative penalties [2] - The board's assessment confirms compliance with the relevant regulations, ensuring the legitimacy of the upcoming transaction [2]

Core Viewpoint - The independent directors of Meinian Onehealth Healthcare Holdings Co., Ltd. have approved a series of proposals regarding the acquisition of equity stakes in multiple companies through a share issuance, which is expected to enhance the company's business structure and profitability [1][2][3]. Group 1: Approval of Proposals - The independent directors have reviewed and approved the proposal for the company to issue shares for asset acquisition, confirming compliance with relevant laws and regulations [1]. - The transaction plan for issuing shares to purchase assets and related party transactions has been deemed reasonable and operable, benefiting the company's business structure and shareholder interests [2]. - The independent directors have also approved the draft report related to the share issuance for asset acquisition, affirming its compliance with legal requirements [2]. Group 2: Transaction Characteristics - The transaction involves acquiring stakes in 11 companies, including Hengyang Meinian Health Checkup Center Co., Ltd., and minority stakes in 5 subsidiaries, including Zhengzhou Meijian Health Management Co., Ltd. [1]. - The transaction is classified as a related party transaction due to the involvement of a company controlled by the actual controller of Meinian [3]. - It has been confirmed that the transaction does not constitute a major asset restructuring as the assets involved do not exceed 50% of the company's relevant financial metrics [4]. Group 3: Compliance and Procedures - The independent directors have confirmed that the transaction adheres to the regulatory requirements for major asset restructuring and does not involve any recent changes in control [4][5]. - The company has fulfilled all necessary legal procedures and submitted valid legal documents for the transaction [7]. - The evaluation agency selected for the transaction has been deemed independent, and the valuation methods used are considered reasonable and fair [7][9]. Group 4: Financial Aspects - The total transaction price for the equity stakes is approximately 427.78 million yuan [9]. - The company has conducted an analysis of the impact of the transaction on immediate returns and has proposed measures to mitigate any potential dilution of returns [8]. Group 5: Authorization and Future Steps - The board of directors has requested authorization from the shareholders' meeting to handle all matters related to the transaction, including adjustments to the transaction plan and execution of necessary agreements [10].

Core Viewpoint - The adjustment of the transaction plan by Meinian Health does not constitute a significant change to the restructuring plan, as confirmed by the independent financial advisor, Guangdong Kai Securities [2][8]. Group 1: Transaction Details - Meinian Health plans to acquire stakes in several health management companies, including 84.00% of Hengyang Meinian, 81.00% of Ningde Meinian, and 75.00% of Yantai Meinian, among others [1][2]. - The transaction involves a total of 14 companies, with varying ownership percentages, including minority stakes in some [1][2]. Group 2: Adjustments to the Transaction Plan - The transaction plan has been adjusted to exclude certain parties and assets, specifically reducing the number of transaction counterparties and the stakes in specific companies [3][4]. - The adjustments include the removal of Chen Xiaoping, Lin Shuping, and Liu Guanghua as transaction counterparties, and the exclusion of stakes in Xiamen Yincheng Meinian, Anxi Meinian, and Nanning Meiyuan Kang [4][8]. Group 3: Compliance with Regulations - The adjustments made to the transaction plan do not exceed the 20% threshold for significant changes as defined by the relevant regulations, thus not requiring a new shareholder meeting for approval [4][8]. - The independent financial advisor has verified that the changes comply with the regulations set forth in the Major Asset Restructuring Management Measures [4][8].

Core Viewpoint - Meinian Health Industry Holdings Co., Ltd. plans to acquire significant stakes in multiple health management and medical examination companies through a share issuance, indicating a strategic expansion in the health sector [1][2]. Group 1: Transaction Details - The transaction involves the acquisition of 84% of Hengyang Meinian Health Examination Center Co., Ltd., 81% of Ningde Meinian Health Management Co., Ltd., 75% of Yantai Meinian Health Examination Management Co., Ltd., and several other companies with varying ownership percentages [1]. - The stakes being acquired include both majority and minority interests in various health management firms across different regions, showcasing a broad geographic expansion strategy [1]. Group 2: Regulatory Compliance - Guangdong Securities Co., Ltd. conducted an independent review and confirmed that the involved parties do not face any regulatory issues related to insider trading or administrative penalties in the last 36 months, ensuring compliance with relevant regulations [2]. - The review concluded that the transaction does not violate any provisions outlined in the "Guidelines for Major Asset Restructuring of Listed Companies" and "Self-Regulatory Guidelines for Listed Companies" [2].

Core Viewpoint - Guotou Zhonglu (600962.SH) has experienced a significant stock price increase, with a cumulative rise of 61.13% over five consecutive trading days, which is notably higher than the Shanghai Composite Index, indicating a substantial risk of stock price volatility [1] Group 1: Company Operations - The company's main business operations and production conditions have not undergone significant changes compared to previously disclosed information [1] - There are no undisclosed major events that require disclosure [1] Group 2: Asset Restructuring - The company is in the process of planning a major asset restructuring, but the auditing, evaluation, and due diligence of the target assets have not yet been completed [1] - There is uncertainty regarding the successful approval and implementation of the restructuring [1]

Core Viewpoint - Chongqing Qin'an Electromechanical Co., Ltd. plans to acquire 99% equity of Anhui Yigao Optoelectronics Technology Co., Ltd. through a combination of share issuance and cash payment, along with raising supporting funds for this transaction [1] Group 1: Stock Price Movement - The company's stock was suspended from trading starting June 30, 2025, due to the planned transaction [1] - The closing price of the stock on May 29, 2025, was 12.61 CNY per share, while the closing price on June 27, 2025, was 16.48 CNY per share, indicating a cumulative increase of 30.69% [1] - Over the 20 trading days prior to the suspension, the stock price increased by 30.69%, with a 28.88% increase after excluding the Shanghai Composite Index's rise of 1.81% and a 32.23% increase after excluding the decline of 1.54% in the Shenwan Automotive Parts II Index [1] Group 2: Compliance and Confidentiality - The company has implemented necessary confidentiality measures during the transaction planning process, limiting the knowledge of sensitive information and adhering to legal and regulatory requirements [2] - The company has completed the required documentation and submissions related to the transaction process as mandated by the Shanghai Stock Exchange [2] - The company will conduct a self-examination of insider trading activities related to the transaction and will submit a query request to the China Securities Depository and Clearing Corporation Limited for stock trading records of relevant parties [2]

Group 1 - The company plans to acquire 99% equity of Anhui Yigao Optoelectronics Technology Co., Ltd. through a combination of issuing shares and cash payment, along with raising supporting funds [1][2] - The board of directors has determined that the transaction is expected to constitute a related party transaction, but it is not anticipated to meet the criteria for a major asset restructuring or a restructuring listing as per the relevant regulations [1][2] - Prior to the transaction, there is no existing relationship between the transaction counterparties and the company, although post-transaction, certain parties may hold more than 5% of the company's total shares, potentially classifying them as related parties [1] Group 2 - The transaction is not expected to result in a change of control of the company, as the actual controller remains the same before and after the transaction [2] - The actual controller has not changed in the past 36 months, indicating stability in the company's governance [2] - The audit and evaluation work for the transaction is still ongoing, and preliminary assessments suggest that the transaction will not meet the standards for a major asset restructuring [1][2]

河南仕佳光子科技股份有限公司董事会 关于本次交易履行法定程序的完备性、合规性 及提交的法律文件的有效性的说明 河南仕佳光子科技股份有限公司（以下简称"公司"或"上市公司"）拟通 过发行股份及支付现金方式购买东莞福可喜玛通讯科技有限公司（以下简称"标 的公司"或"福可喜玛"）股权并募集配套资金（以下简称"本次交易"）。本 次交易完成后，福可喜玛将成为上市公司的控股子公司。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司重大 资产重组管理办法》（以下简称"《重组管理办法》"）、《上海证券交易所科 创板股票上市规则》《上市公司信息披露管理办法》等法律、法规和规范性文件 及《河南仕佳光子科技股份有限公司章程》（以下简称"《公司章程》"）的相 关规定，公司董事会对于公司本次交易履行法定程序的完备性、合规性以及提交 的法律文件的有效性进行了认真审核，并说明如下： 一、关于本次交易履行法定程序完备性、合规性的说明 的有关规定，采取了严格的保密措施，尽可能缩小内幕信息知情人员的范围，严 格履行了本次交易信息在依法披露前的保密义务。 备忘录。 购买资产协议》。 内累计涨跌幅超过20%。在剔除同行业板块因素影响后 ...